GXO Logistics Inc vs TransMedics Group Inc — how do they compare? GXO Logistics Inc trades at $53.58 (market cap $6.07B), while TransMedics Group Inc trades at $74.79 (market cap $2.54B). The key difference: GXO Logistics Inc is far larger — about 2.4× TransMedics Group Inc's market cap, and GXO Logistics Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| GXO | TMDX | |
|---|---|---|
Market Cap | $6.07B | $2.54B |
Sector | Industrials | Technology |
52-Week High | $65.59 | $150.42 |
52-Week Low | $45.52 | $61.99 |
Enterprise Value | $11.24B | $2.94B |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $52.80, down 2.31% today, with strong analyst support showing 16 buy ratings and an average price target of $66.60. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.50 surpassing the $0.37 estimate. Technical indicators show a bullish trend with moving averages supporting upward momentum, while fundamentals reveal revenue growth to $13.18 billion in 2025 with improving profitability margins expected in 2026.
GXO presents a compelling investment case with 36% upside to consensus targets, supported by strong earnings momentum and expanding partnerships. Key risks include competitive pressures in logistics and Amazon's market entry, while the company's focus on high-growth verticals and record sales pipeline provides growth catalysts. The stock's current valuation at 48.26 P/E requires continued execution to justify premium multiples.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →